30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
KY Biotechnology & Medical Research

NovaBridge Biosciences (NBP)

Track

Over the last 90 days, NovaBridge Biosciences has seen a net insider buy of $492,131.98, with total buys amounting to $577,300 and sells totaling $128,680.87. A significant buy of $577,300 was made by Mark Arnold Hagler. Several executives, including the Chief Medical Officer and SVP of Clinical Development, have made sales.
Stock chart
Ticker: NBP Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Dennis Phillip Andrew
Chief Medical Officer
2 sales — total 200,000 USD
Sale 18 Jun 2026
Value US$2,534,985.14 | Price 433.81 | Shares 67,688
Sale 18 Jun 2026
Value US$4,886,837.69 | Price 71.77 | Shares 19,334
Sale 1 Jun 2026
Value US$3,706,587.46 | Price 345.69 | Shares 49,998
Sale 14 May 2026
Value US$42,584.01 | Price 1.99 | Shares 21,399
Sale 14 May 2026
Value US$42,584.01 | Price 1.99 | Shares 21,399
Proposed sale 14 May 2026
Value US$18,534.41 | Price 1.99 | Shares 9,304
Buy 24 Apr 2026
Value US$577,300.00 | Price 2.51 | Shares 230,000
Proposed sale 18 Mar 2026
Value US$10,153.29 | Price 2.79 | Shares 3,638
Proposed sale 2 Jan 2026
Value US$519,600.00 | Price 4.33 | Shares 120,000
Proposed sale 18 Dec 2025
Value US$14,501.46 | Price 4.23 | Shares 3,431
Proposed sale 26 Jul 2024
Value US$69,500.00 | Price 1.39 | Shares 50,000
Proposed sale 17 Jul 2024
Value US$489,000.00 | Price 1.63 | Shares 300,000
Proposed sale 15 Mar 2024
Value US$270.00 | Price 1.80 | Shares 150
Proposed sale 8 Feb 2024
Value US$40,000.00 | Price 2.00 | Shares 20,000
Proposed sale 5 Jan 2024
Value US$63,600.00 | Price 2.12 | Shares 30,000
Proposed sale 29 Dec 2023
Value US$156,831.00 | Price 1.83 | Shares 85,700
Proposed sale 26 Dec 2023
Value US$31,000.00 | Price 1.55 | Shares 20,000
Proposed sale 24 Oct 2023
Value US$4,466,416.50 | Price 0.73 | Shares 6,078,555
Proposed sale 29 Sep 2023
Value US$3,810.00 | Price 1.27 | Shares 3,000
Proposed sale 11 Jul 2023
Value US$80,040.00 | Price 2.76 | Shares 29,000
Proposed sale 5 Jul 2023
Value US$286,062.00 | Price 2.94 | Shares 97,300
Proposed sale 5 Jul 2023
Value US$69,972.00 | Price 2.94 | Shares 23,800
Proposed sale 5 Jul 2023
Value US$52,332.00 | Price 2.94 | Shares 17,800
Proposed sale 1 May 2023
Value US$101,640.00 | Price 3.08 | Shares 33,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-22 2026-06-18 S Sale
Dennis Phillip Andrew

Chief Medical Officer

Officer
67,688 -17.3%
433.81
US$2,534,985 		67,688 -17.3% 433.81 US$2,534,985
2026-06-22 2026-06-18 S Sale
Dennis Phillip Andrew

Chief Medical Officer

Officer
19,334 -27.1%
71.77
US$4,886,838 		19,334 -27.1% 71.77 US$4,886,838
2026-06-02 2026-06-01 S Sale
Xu Cong Claire

SVP, Clinical Development

Officer
49,998 -49.1%
345.69
US$3,706,587 		49,998 -49.1% 345.69 US$3,706,587
2026-05-18 2026-05-14 S Sale
Cao Sean Wuxiong

See Remarks

Executive Director
21,399 -37.9%
1.99
US$42,584 		21,399 -37.9% 1.99 US$42,584
2026-05-18 2026-05-14 S Sale
Cao Sean Wuxiong

See Remarks

Executive Director
21,399 -37.9%
1.99
US$42,584 		21,399 -37.9% 1.99 US$42,584
2026-05-14 2026-05-14 PrS Proposed sale
Cao Sean Wuxiong

Officer; CHIEF BUSINESS DEVELOPMENT OFFICER

Officer
9,304
1.99
US$18,534 		9,304 1.99 US$18,534
2026-04-28 2026-04-24 B Purchase
Hagler Mark Arnold

See Remarks

Officer
230,000 +inf%
2.51
US$577,300 		230,000 +inf% 2.51 US$577,300
2026-03-18 2026-03-18 PrS Proposed sale
Dennis Phillip Andrew

Chief Medical Officer

Officer
3,638
2.79
US$10,153 		3,638 2.79 US$10,153
2026-01-02 2026-01-02 PrS Proposed sale
Skelton Joseph W.

Officer; FORMER CFO

Officer
120,000
4.33
US$519,600 		120,000 4.33 US$519,600
2025-12-18 2025-12-18 PrS Proposed sale
Dennis Phillip Andrew

CHIEF MEDICAL OFFICER

Officer
3,431
4.23
US$14,501 		3,431 4.23 US$14,501
2024-07-26 2024-07-26 PrS Proposed sale
KANNAN RAJ

Officer; CEO

Officer
50,000
1.39
US$69,500 		50,000 1.39 US$69,500
2024-07-17 2024-07-17 PrS Proposed sale
KANNAN RAJ

Officer; CEO

Officer
300,000
1.63
US$489,000 		300,000 1.63 US$489,000
2024-03-15 2024-03-15 PrS Proposed sale
Feng Gigi Qi

Officer; CHIEF COMMUNICATIONS OFFICER

Officer
150
1.80
US$270 		150 1.80 US$270
2024-02-08 2024-02-08 PrS Proposed sale
Tang Weimin

Officer; CHIEF BUSINESS OFFICER

Officer
20,000
2.00
US$40,000 		20,000 2.00 US$40,000
2024-01-05 2024-01-05 PrS Proposed sale
Zhu Andrew

Officer; PRESIDENT AND ACTING CEO

Officer
30,000
2.12
US$63,600 		30,000 2.12 US$63,600
2023-12-29 2023-12-29 PrS Proposed sale
Li Richard Cheng

Officer; CHIEF LEGAL OFFICER

Officer
85,700
1.83
US$156,831 		85,700 1.83 US$156,831
2023-12-26 2023-12-26 PrS Proposed sale
Feng Gigi Qi

Officer; CHIEF COMMUNICATION OFFICER

Officer
20,000
1.55
US$31,000 		20,000 1.55 US$31,000
2023-10-10 2023-10-24 PrS Proposed sale
Everest Medicines Ltd

10% Stockholder

Large shareholder
6,078,555
0.73
US$4,466,416 		6,078,555 0.73 US$4,466,416
2023-09-29 2023-09-29 PrS Proposed sale
Tang Weimin

Officer; CHIEF BUSINESS OFFICER

Officer
3,000
1.27
US$3,810 		3,000 1.27 US$3,810
2023-07-11 2023-07-11 PrS Proposed sale
Hayslip John

Officer; CHIEF MEDICAL OFFICER

Officer
29,000
2.76
US$80,040 		29,000 2.76 US$80,040
2023-07-05 2023-07-05 PrS Proposed sale
Zhu Andrew

Officer; PRESIDENT

Officer
97,300
2.94
US$286,062 		97,300 2.94 US$286,062
2023-07-05 2023-07-05 PrS Proposed sale
Tang Weimin

Officer; CHIEF BUSINESS OFFICER

Officer
23,800
2.94
US$69,972 		23,800 2.94 US$69,972
2023-07-05 2023-07-05 PrS Proposed sale
Li Richard Cheng

Officer; CHIEF LEGAL OFFICER

Officer
17,800
2.94
US$52,332 		17,800 2.94 US$52,332
2023-05-01 2023-05-01 PrS Proposed sale
Yeh Richard

Officer; COO interim CFO

Officer
33,000
3.08
US$101,640 		33,000 3.08 US$101,640
Explore more

More insider trading research around NovaBridge Biosciences

More insider trades in KY
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity